Different Types of Stem Cells and Their Use

Stem cells have the unique ability to develop into many different types of cells in the body. They play a critical role in the growth and development of organisms and are responsible for repairing damaged tissues. Stem cells derived from cord blood have been used for more than 30 years in various medical treatments, including childhood Leukemia and Sickle Cell Disease. Other sources of stem cells such as cord tissue and placental tissue have also been explored for their potential therapeutic applications. Exosomes, while not stem cells, are also being tested as a biobanking treatment method.

Let’s discuss the different types of stem cells and how they can be used to help treat illnesses.

Cord blood is the blood that remains in the umbilical cord after a baby is born. It contains stem cells that are genetically unique to the newborn and their family.

These stem cells are extracted from the cord blood after birth and cryogenically frozen for future use. Cord blood stem cells can be used to treat a variety of medical conditions, including blood disorders, immune system disorders, and some genetic disorders.

Cord blood stem cells have been used for several decades in the treatment of various blood disorders. In particular, hematopoietic stem cells (HSCs) found in cord blood have been shown to be highly effective in the treatment of leukemia, lymphoma, and sickle cell anemia. HSCs are responsible for producing all the cells in our blood, including red blood cells, white blood cells, and platelets. In individuals with blood disorders, these cells may be defective or diseased, leading to a range of health problems.

Cord blood stem cells can be used to treat immune system disorders such as severe combined immunodeficiency (SCID), also known as the “bubble boy” disease. In SCID, the patient’s immune system is severely compromised, making them vulnerable to infections. SCID is a genetic disorder that affects the development and function of immune cells, leaving the patient with a severely compromised immune system. Individuals with SCID are highly susceptible to infections and often require lifelong medical management. Cord blood stem cells can be used to replace the defective immune cells in patients with SCID, restoring their immune system and protecting them from infections.

Cord blood stem cells can also be used to treat some genetic disorders such as Hurler syndrome, Krabbe disease, and metachromatic leukodystrophy. Genetic disorders are caused by mutations or defects in genes, which can lead to a wide range of health problems. Some genetic disorders affect specific organs or systems in the body, while others can affect multiple organs and systems. Cord blood stem cells can be used to replace the defective cells, thereby restoring the enzyme’s function. While not all genetic disorders can be treated with cord blood stem cells, this therapy offers a promising avenue for the development of new treatments and improved patient outcomes.

Cord tissue is the connective tissue that surrounds the blood vessels in the umbilical cord. It contains a different type of stem cell called mesenchymal stem cells (MSCs). MSCs have the unique ability to differentiate into various cell types, including bone, cartilage, and fat cells. These cells have been studied extensively for their potential use in regenerative medicine.

Cord tissue stem cells have been used to treat orthopedic conditions such as arthritis, joint injuries, and spinal cord injuries. These stem cells can differentiate into cartilage and bone cells, making them ideal for repairing damaged tissues. Orthopedic conditions can be caused by a variety of factors, including injury, disease, or age-related wear and tear, and can lead to chronic pain, limited mobility, and reduced quality of life. Cord tissue stem cells have shown promising results in the treatment of a wide range of orthopedic conditions, making them an exciting area of research for the field of regenerative medicine.

Cord tissue stem cells have also been studied for their potential use in the treatment of cardiovascular conditions such as heart failure and myocardial infarction. These stem cells can differentiate into heart muscle cells, promoting the regeneration of damaged heart tissue. Research into this use is still in the early stages, but studies have shown promising results.

The placenta is a unique organ that plays a crucial role in the development of the fetus during pregnancy. It not only provides essential nutrients and oxygen to the growing fetus, but also helps to remove waste products from the fetal circulation. It contains several different types of stem cells, including MSCs and HSCs. Placental stem cells have been shown to have regenerative and immunomodulatory properties, making them an attractive candidate for the treatment of a variety of conditions.

Placental tissue stem cells have been studied for their potential use in wound healing. These stem cells can differentiate into skin cells, promoting the regeneration of damaged tissue and accelerating the healing process. Placental tissue stem cells have shown promise in treating a variety of wounds, including chronic wounds and burns.

Placental tissue stem cells have also shown promise in the treatment of neurological disorders such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. These stem cells can differentiate into nerve cells, promoting the regeneration of damaged neurons and improving neurological function.

Exosomes are not stem cells, but small vesicles that are secreted by cells and contain various molecules, including proteins, nucleic acids, and microRNAs. They play a crucial role in intercellular communication and have been studied extensively for their potential therapeutic applications.

Exosomes have been studied for their potential use in the treatment of inflammatory conditions such as arthritis and inflammatory bowel disease. These vesicles can modulate the immune response and reduce inflammation, thereby alleviating symptoms associated with these conditions.

Exosomes have also been studied for their potential use in the treatment of neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease. These vesicles can transfer molecules that promote neuronal survival and improve neurological function.

Stem cells derived from cord blood, cord tissue, and placental tissue have shown immense potential in the field of regenerative medicine. Cord blood stem cells have been used for more than 30 years in the treatment of various medical conditions, including 80 FDA-approved treatments. And other sources of stem cells (cord tissue and placental tissue) and cell communicators (exosomes) are being extensively studied for their potential applications. As research in this field continues, it is hoped that these therapies will become more widely available and provide new and innovative treatments for a range of medical conditions.

Sources

Stem Cell Basics: NIH

Cord Blood FAQs: Parents Guide to Cord Blood

Mayo Clinic: Cord Blood Banking

Barker, J. N., et al. “Dose-Adjusted HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Hematologic Malignancies.” Blood, vol. 102, no. 5, 2003, pp. 1601–7., doi:10.1182/blood-2003-01-0058.

Pai, S. Y., et al. “Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009.” New England Journal of Medicine, vol. 371, no. 5, 2014, pp. 434–46., doi:10.1056/nejmoa1401177.

Koc, O. N., et al. “Allogeneic Mesenchymal Stem Cell Infusion for Treatment of Metachromatic Leukodystrophy (MLD) and Hurler Syndrome (MPS-IH).” Bone Marrow Transplantation, vol. 30, no. 4, 2002, pp. 215–22., doi:10.1038/sj.bmt.1703629.

Vangsness, C. T., Jr., et al. “Adult Human Mesenchymal Stem Cells Delivered via Intra-Articular Injection to the Knee Following Partial Medial Meniscectomy: A Randomized, Double-Blind, Controlled Study.” Journal of Bone and Joint Surgery, vol. 96, no. 2, 2014, pp. 90–8., doi:10.2106/JBJS.M.00058.

Davatchi, F., et al. “Mesenchymal Stem Cell Therapy for Knee Osteoarthritis. Preliminary Report of Four Patients.” International Journal of Rheumatic Diseases, vol. 16, no. 2, 2013, pp. 211–15., doi:10.1111/1756-185X.12074.

Ankrum, J. A., et al. “Mesenchymal Stem Cells: Immune Evasive, Not Immune Privileged.” Nature Biotechnology, vol. 32, no. 3, 2014, pp. 252–60., doi:10.1038/nbt

The views, statements, and pricing expressed are deemed reliable as of the published date. Articles may not reflect current pricing, offerings, or recent innovations.